Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Current Assets (2016 - 2025)

Syndax Pharmaceuticals has reported Current Assets over the past 11 years, most recently at $528.1 million for Q4 2025.

  • Quarterly results put Current Assets at $528.1 million for Q4 2025, down 12.43% from a year ago — trailing twelve months through Dec 2025 was $528.1 million (down 12.43% YoY), and the annual figure for FY2025 was $528.1 million, down 12.43%.
  • Current Assets for Q4 2025 was $528.1 million at Syndax Pharmaceuticals, roughly flat from $529.8 million in the prior quarter.
  • Over the last five years, Current Assets for SNDX hit a ceiling of $603.1 million in Q4 2024 and a floor of $238.3 million in Q3 2021.
  • Median Current Assets over the past 5 years was $443.8 million (2023), compared with a mean of $437.8 million.
  • Biggest five-year swings in Current Assets: skyrocketed 167.69% in 2021 and later decreased 12.43% in 2025.
  • Syndax Pharmaceuticals' Current Assets stood at $448.4 million in 2021, then increased by 9.23% to $489.8 million in 2022, then grew by 18.6% to $580.9 million in 2023, then rose by 3.82% to $603.1 million in 2024, then decreased by 12.43% to $528.1 million in 2025.
  • The last three reported values for Current Assets were $528.1 million (Q4 2025), $529.8 million (Q3 2025), and $531.7 million (Q2 2025) per Business Quant data.